AVM Biotechnology LLC   Report issue

For profit Phase 2
Founded: Seattle WA United States (2008)

Organization Overview

First Clinical Trial
2020
NCT04366115
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

AVM Biotechnology LLC

Active Ingredients

Drugs in Phase 2 Trials (2)

avm0703 (1 trial)

hydrocortisone (solu-cortef) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Neoplasms (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2